Cross-presentation of cell-associated antigens by MHC class I in dendritic cell subsets

Abstract

Dendritic cells (DCs) have the unique ability to pick up dead cells carrying antigens in tissue and migrate to the lymph nodes where they can cross-present cell-associated antigens by MHC class I to CD8+ T cells. There is strong in vivo evidence that the mouse XCR1+ DCs subset acts as a key player in this process. The intracellular processes underlying cross-presentation remain controversial and several pathways have been proposed. Indeed, a wide number of studies have addressed the cellular process of cross-presentation in vitro using a variety of sources of antigen and antigen-presenting cells. Here, we review the in vivo and in vitro evidence supporting the current mechanistic models and disscuss their physiological relevance to the cross-presentation of cell-associated antigens by DCs subsets.

Tissue-Specific Control of Tissue-Resident Memory T Cells

“…This subset of DCs develop in a transcription factor Batf3-dependent manner and exhibit superior capacity to cross-Present exogenous antigen to CD8 + T cells. 38,39 Interestingly, it is in the draining lymph node (LN) during the very early phase of naïve CD8 + T cell priming that DNGR1 + DCs deliver critical signals to instruct CD8 + T cells to differentiate into skin T RM at later stages. 37 Cross-Priming DCs extend the retention of activated CD8 + T cells in draining LNs via repressing transcription factor Kruppel Like Factor 2 (K1f2) and its target Sphingosine-1-Phosphate Receptor 1 (S1pr1).…”

A Critical Analysis of the Role of SNARE Protein SEC22B in Antigen Cross-Presentation

“…Disrupting any of these steps can alter cross-presentation (Joffre et al, 2012). At the antigen uptake stage, manipulation of endo- and phagocytic receptors modulates cross-presentation (Burgdorf et al, 2006; Gutierrez-Martinez et al, 2015; Mintern et al, 2015). Subsequent processing of internalized antigen is also highly regulated.…”

Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses

“…[2] Notably, DCs are endowed with a unique antigen processing pathway that enables exogenous antigens to undergo proteasomal degradation and be presented in the context of MHC-I molecules to CD8 + cytotoxic T cells, in a process called cross-presentation. [9, 10] Furthermore, high affinity peptides bind directly to MHC-I, without previous endocytosis and processing. [11] Since most tumor-associated antigens used for DC vaccination are of exogenous origin, strategies that foment antigen presentation through MHC-I are crucial for the generation of CD8 + cytotoxic T cell response, and thereby, for the generation of an anti-tumor immune response.…”